Type II endometrial cancer: Incidence, overall and disease-free survival in Martinique

被引:13
作者
Ebring, Coralie [1 ]
Marlin, Regine [2 ]
Macni, Jonathan [3 ]
Vallard, Alexis [4 ]
Bergerac, Sebastien [5 ]
Beaubrun-Renard, Murielle [2 ]
Joachim, Clarisse [2 ]
Jean-Laurent, Mehdi [1 ]
机构
[1] CHU Martinique, Maison Femme Mere & Enfant, Serv Gynecol, Fort De France, Martinique, France
[2] CHU Martinique, Unite Genet Mol Canc, Fort De France, Martinique, France
[3] CHU Martinique, UF Registre Gen Canc Martinique 1441, Pole Cancerol Hematol Urol, Fort De France, Martinique, France
[4] CHU Martinique, Pole Cancerol Hematol Urol, Fort De France, Martinique, France
[5] CHU Martinique, Serv Med Nucl, Fort De France, Martinique, France
来源
PLOS ONE | 2023年 / 18卷 / 03期
关键词
CLEAR-CELL; CARCINOMA; ADENOCARCINOMA; PROGNOSIS; OUTCOMES;
D O I
10.1371/journal.pone.0278757
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background and study aimsIn Martinique, about 33 new cases of endometrial cancer are diagnosed per year with a high mortality rate (world standardised rate of 4.9/100,000 versus 2.3/100,000 in mainland France). The present study aimed to determine the incidence and mortality of type I and type II endometrial cancers (ECs), their overall survival (OS) and disease-free survival (DFS) between 2012 and 2016. Patients and methodsThis retrospective observational cohort study used data from the Martinique Cancer Registry (MCR). 191 patients with corpus uterine cancer were extracted between 2012 and 2016. Patients with either endometrioid endometrial carcinoma (EEC), uterine papillary serous carcinomas (UPSC), uterine clear cell carcinomas (UCCC) or uterine carcinosarcomas (UCS) were included. All other uterine cancers were excluded. ResultsAmong the 163 included patients, 97 (60%) were type I and 66 (40%) were type II. The standardized incidence rate is 4.50/100,000 for type I vs. 2.66/100,000 for type II. Three years DFS for all types, type I and type II was 81.5% [74.2-86.9], 84.9% [75.4-91] and 76.7% [63.8-85.5] respectively. The five-years OS for all types, type I and type II was 47.0% [38.9-54.7] vs. 58.8% [47.3-68.5] vs. 22.8% [15.0-37.7] respectively. ConclusionsIn Martinique, we report a high proportion of type II ECs, which has a poor prognosis with few treatment options.
引用
收藏
页数:13
相关论文
共 34 条
  • [1] [Anonymous], 2018, TUMEURS SOLIDES, V1, P372
  • [2] Lynch syndrome and endometrial cancer
    Bats, Anne-Sophie
    Rossi, Lea
    Le Frere-Belda, Marie-Aude
    Narjoz, Celine
    Cournou, Caroline
    Gosset, Marie
    Ngo, Charlotte
    Delomenie, Myriam
    Nos, Claude
    Blons, Helene
    Laurent-Puig, Pierre
    Lecuru, Fabrice
    [J]. BULLETIN DU CANCER, 2017, 104 (12) : 1013 - 1021
  • [3] Applications and analysis of targeted genomic sequencing in cancer studies
    Bewicke-Copley, Findlay
    Kumar, Emil Arjun
    Palladino, Giuseppe
    Korfi, Koorosh
    Wang, Jun
    [J]. COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL, 2019, 17 : 1348 - 1359
  • [4] 2 PATHOGENETIC TYPES OF ENDOMETRIAL CARCINOMA
    BOKHMAN, JV
    [J]. GYNECOLOGIC ONCOLOGY, 1983, 15 (01) : 10 - 17
  • [5] Uterine serous and Grade 3 endometrioid carcinomas - Is there a survival difference?
    Boruta, DM
    Gehrig, PA
    Groben, PA
    Bae-Jump, V
    Boggess, JF
    Fowler, WC
    Van Le, L
    [J]. CANCER, 2004, 101 (10) : 2214 - 2221
  • [6] Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium
    Creasman, WT
    Kohler, MF
    Odicino, F
    Maisonneuve, P
    Boyle, P
    [J]. GYNECOLOGIC ONCOLOGY, 2004, 95 (03) : 593 - 596
  • [7] Uterine papillary serous cancer: A review of the literature
    del Carmen, Marcela G.
    Birrer, Michael
    Schorge, John O.
    [J]. GYNECOLOGIC ONCOLOGY, 2012, 127 (03) : 651 - 661
  • [8] Cancer incidence in Martinique: a model of epidemiological transition
    Dieye, Moustapha
    Veronique-Baudin, Jacqueline
    Draganescu, Cyprian
    Azaloux, Herve
    [J]. EUROPEAN JOURNAL OF CANCER PREVENTION, 2007, 16 (02) : 95 - 101
  • [9] Integrated genomic characterization of endometrial carcinoma
    Getz, Gad
    Gabriel, Stacey B.
    Cibulskis, Kristian
    Lander, Eric
    Sivachenko, Andrey
    Sougnez, Carrie
    Lawrence, Mike
    Kandoth, Cyriac
    Dooling, David
    Fulton, Robert
    Fulton, Lucinda
    Kalicki-Veizer, Joelle
    McLellan, Michael D.
    O'Laughlin, Michelle
    Schmidt, Heather
    Wilson, Richard K.
    Ye, Kai
    Ding, Li
    Mardis, Elaine R.
    Ally, Adrian
    Balasundaram, Miruna
    Birol, Inanc
    Butterfield, Yaron S. N.
    Carlsen, Rebecca
    Carter, Candace
    Chu, Andy
    Chuah, Eric
    Chun, Hye-Jung E.
    Dhalla, Noreen
    Guin, Ranabir
    Hirst, Carrie
    Holt, Robert A.
    Jones, Steven J. M.
    Lee, Darlene
    Li, Haiyan I.
    Marra, Marco A.
    Mayo, Michael
    Moore, Richard A.
    Mungall, Andrew J.
    Plettner, Patrick
    Schein, Jacqueline E.
    Sipahimalani, Payal
    Tam, Angela
    Varhol, Richard J.
    Robertson, A. Gordon
    Pashtan, Itai
    Saksena, Gordon
    Onofrio, Robert C.
    Schumacher, Steven E.
    Tabak, Barbara
    [J]. NATURE, 2013, 497 (7447) : 67 - 73
  • [10] The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future
    Goebel, Emily A.
    Vidal, August
    Matias-Guiu, Xavier
    Gilks, C. Blake
    [J]. VIRCHOWS ARCHIV, 2018, 472 (06) : 885 - 896